Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of YR001 in Healthy Volunteers
NCT05718921Phase 1Completed
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YR001 in atopic dermatitis (AD) and psoriasis (12 arms), sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd. Primary endpoint: Safety and Maximum Tolerate Dose. Started Apr 2023; status: completed.
02
Drugs
YR001
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on NCT05718921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718921.